Lopes E, Ribeiro M M, Silva M J, Gandra M, Principe F, Granato C
Clinical Hematology Department, Hospital S. Joao, Porto, Portugal.
Leukemia. 1992;6 Suppl 3:138S-140S.
The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyurea (HU) in conventional dosage. A clinical response was seen in seven patients treated with IFN-alpha 2b (4 CR and 2 PR), and in four patients treated with HU (3 CR and 1 PR). No significant side effects were observed. Our findings indicate that IFN-alpha 2b offers a non-leukaemogenic and very promising therapeutic alternative for E.T.
作者分析了1983年至1991年期间诊断出的12例有症状的原发性血小板增多症（E.T.）患者。出血和血栓形成现象是主要的临床表现。治疗主要包括皮下注射α-干扰素（IFN-α 2b），剂量为3至5 MU/m²，以及常规剂量的羟基脲（HU）。接受IFN-α 2b治疗的7例患者出现了临床反应（4例完全缓解和2例部分缓解），接受HU治疗的4例患者也出现了临床反应（3例完全缓解和1例部分缓解）。未观察到明显的副作用。我们的研究结果表明，IFN-α 2b为原发性血小板增多症提供了一种无致白血病性且非常有前景的治疗选择。
